Fig. 1: Response rates and progression-free survival with bavituximab plus pembrolizumab in HCC. | Nature Communications

Fig. 1: Response rates and progression-free survival with bavituximab plus pembrolizumab in HCC.

From: The phosphatidylserine targeting antibody bavituximab plus pembrolizumab in unresectable hepatocellular carcinoma: a phase 2 trial

Fig. 1: Response rates and progression-free survival with bavituximab plus pembrolizumab in HCC.The alternative text for this image may have been generated using AI.

a Waterfall plot depicts best percentage change in tumor dimensions from baseline per RECIST 1.1 among evaluable patients (n = 28). Asterisks indicates patients with new lesions demonstrating PD. ORR objective response rate, PR partial response, CR complete response, SD stable disease, PD progressive disease. b Kaplan-Meier curve shows the probability of progression-free survival over time among evaluable patients. Source data are provided as a Source data file.

Back to article page